Abstract

e22510Background: According to the results of the SSG XVIII/AIO trial, adjuvant imatinib administered at 400 mg/day for the duration of 3 years is a standard treatment in patients with high risk of...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Adherence to Guidelines for Adjuvant Imatinib Therapy for GIST: A Multi-institutional Analysis
Danielle A Bischof ... Malcolm H Squires
Journal of Gastrointestinal Surgery | VOL. 19
Danielle A Bischof, et. al.Danielle A Bischof ... Malcolm H Squires
03 Mar 2015
Adjuvant therapy in primary GIST: state-of-the-art
P Reichardt ... H Joensuu
Annals of Oncology | VOL. 23
P Reichardt, et. al.P Reichardt ... H Joensuu
01 Nov 2012
Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure
Jian Li ... Jing Gao
Chinese Journal of Gastrointestinal Surgery | VOL. 19
Jian Li, et. al.Jian Li ... Jing Gao
25 Nov 2016
A high risk group in the modified national institutes of health consensus criteria for the gastrointestinal stromal tumor: a clear indication of the adjuvant imatinib.
Dong Kyung Chang
Intestinal research | VOL. 12
Dong Kyung ChangDong Kyung Chang
01 Jan 2014
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Health disparity viewed from public historic cancer mortality data in the US: Advocacy for gastrointestinal cancers, for tailored prevention measures, and for inter-agency population data harmonization.
Tingting Zhang ... Tony Hung
Journal of Clinical Oncology | VOL. 42
Tingting Zhang, et. al.Tingting Zhang ... Tony Hung
10 Aug 2024
Racial impact of secondary metastasis in patients with lung cancer: Evidence of US hospitals in 2020.
Thanathip Suenghataiphorn ... Soravis Alm Osataphan
Journal of Clinical Oncology | VOL. 42
Thanathip Suenghataiphorn, et. al.Thanathip Suenghataiphorn ... Soravis Alm Osataphan
10 Aug 2024
Validation of a chemotherapy toxicity prediction model in older adults with cancer in Taiwan.
Chieh-Ying Chang ... Wen-Chi Chou
Journal of Clinical Oncology | VOL. 42
Chieh-Ying Chang, et. al.Chieh-Ying Chang ... Wen-Chi Chou
10 Aug 2024
Comparative analysis of cirrhosis and hepatocellular carcinoma outcomes in Asian populations with non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatohepatitis liver disease (MASLD): A five-year retrospective study.
Yuan-Tsung Tseng ... Chun-Hsiang Wang
Journal of Clinical Oncology | VOL. 42
Yuan-Tsung Tseng, et. al.Yuan-Tsung Tseng ... Chun-Hsiang Wang
10 Aug 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.